Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 3/20 | 0.59 |
| ▸ | NPY2R | P49146 | 1/20 | 0.59 |
| ▸ | NPY4R | P50391 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | APEX1 | P27695 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | NOS2 | P35228 | 1/20 | 0.53 |
| ▸ | C3AR1 | Q16581 | 6/20 | 0.50 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.48 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | NRP1 | O14786 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29494597 | 0.95 | NPY1R (0.66) | NPY1RNPY2RNPY4RCYP1A2GLA | |
| SCHEMBL27898034 | 0.87 | CYP2C19 (0.65) | NPY1RNPY2RNPY4RCYP1A2GLA | |
| SCHEMBL1735525 | 0.87 | CYP2C19 (0.65) | NPY1RNPY2RNPY4RCYP1A2GLA | |
| SCHEMBL29603738 | 0.85 | CYP1A2 (0.61) | NPY1RNPY2RNPY4RCYP1A2GLA | |
| SCHEMBL29957673 | 0.85 | CYP1A2 (0.57) | NPY1RNPY2RNPY4RCYP1A2GLA | |
| SCHEMBL30391184 | 0.85 | CYP1A2 (0.61) | NPY1RNPY2RNPY4RCYP1A2GLA | |
| SCHEMBL28409679 | 0.85 | CYP1A2 (0.61) | NPY1RNPY2RNPY4RCYP1A2GLA | |
| SCHEMBL29356389 | 0.85 | CYP1A2 (0.61) | NPY1RNPY2RNPY4RCYP1A2GLA | |
| SCHEMBL30114897 | 0.85 | CYP1A2 (0.57) | NPY1RNPY2RNPY4RCYP1A2GLA | |
| Acetic Acid SCHEMBL29358131 | 0.84 | NPY1R (0.59) | NPY1RNPY2RNPY4RCYP1A2GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001910-A1 | PEPTIDES AND USES THEREOF | PREVECEUTICAL MEDICAL INC (CA) | 2026-01-01 | — | — | US | claimed |
| EP-4433495-A1 | PEPTIDES AND USES THEREOF | Preveceutical Medical Inc. (CA) | 2024-09-25 | — | — | EP | claimed |
| US-12097237-B2 | Small molecule Ras inhibitors | OHIO STATE INNOVATION FOUNDATION (US) | 2024-09-24 | — | — | US | claimed |
| CN-118221777-A | Polypeptide for repairing skin wound or mucous membrane injury and application thereof | 四川好医生攀西药业有限责任公司 | 2024-06-21 | — | — | CN | claimed |
| CN-117677302-A | Peptide compounds for flavor modulation | CJ第一制糖株式会社 | 2024-03-08 | — | — | CN | claimed |
| CN-116621933-A | Targeted liposome for treating glioblastoma, and preparation method and application thereof | 中国科学院近代物理研究所 | 2023-08-22 | — | — | CN | claimed |
| CN-113929745-B | Polypeptide for treating rhinitis and liquid composition containing polypeptide | 广煜医药科技(宁夏)有限公司 | 2023-08-18 | — | — | CN | claimed |
| WO-2023089542-A1 | PEPTIDES AND USES THEREOF | PreveCeutical Medical Inc. (CA) | 2023-05-25 | — | — | WO | claimed |
| CN-116102635-A | Cathelicidin family polypeptide from aquatic mammal, and preparation method and application thereof | 中国药科大学 | 2023-05-12 | — | — | CN | claimed |
| CN-115677833-A | Tumor affinity peptide for human epidermal growth factor receptor 2 (HER 2) | 中国药科大学 | 2023-02-03 | — | — | CN | claimed |
| WO-2022148418-A1 | PHARMACEUTICAL COMPOSITION CAPABLE OF BEING DELIVERED BY METERED DOSE INHALER | 江苏恒瑞医药股份有限公司 | 2022-07-14 | — | — | WO | claimed |
| CN-114599384-B | Stable parenteral dosage form of cetrorelix acetate | SUN PHARMACEUTICAL INDUSTRIES LTD. (IN) | 2026-05-26 | — | — | CN | disclosed |
| CN-115298194-B | VIPR2 antagonistic peptide | 一丸自然美健有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20260124255-A1 | Salmonella vectored therapies for treatment of cancer | UNIV FLORIDA (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260001910-A1 | PEPTIDES AND USES THEREOF | PREVECEUTICAL MEDICAL INC (CA) | 2026-01-01 | — | — | US | disclosed |
| CN-114599384-A | Stable parenteral dosage form of cetrorelix acetate | 太阳医药工业有限公司 | 2022-06-07 | — | — | CN | disclosed |
| US-20220153802-A1 | A STABLE PARENTERAL DOSAGE FORM OF CETRORELIX ACETATE | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2022-05-19 | — | — | US | disclosed |
| US-20220143146-A1 | PEPTIDE YY PHARMACEUTICAL FORMULATIONS, COMPOSITIONS, AND METHODS | GILA THERAPEUTICS, INC. | 2022-05-12 | — | — | US | disclosed |
| EP-3971215-A2 | ARTIFICIAL MULTI-ANTIGEN FUSION PROTEIN AND PREPARATION AND USE THEREOF | Oxford Vacmedix UK Ltd. (GB) | 2022-03-23 | — | — | EP | disclosed |
| US-20220047649-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER USING BACTERIA | INDAPTUS THERAPEUTICS, INC. | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12097237-B2 | Small molecule Ras inhibitors | KRAS, HRAS, NRAS | NPY1R 4859/4885NPY2R 4865/4885NPY4R 4878/4885 |
| US-20260001910-A1 | PEPTIDES AND USES THEREOF | MMP3, PEPD, MMP9 | NPY1R 51/4885NPY2R 38/4885NPY4R 63/4885 |
| US-20260124255-A1 | Salmonella vectored therapies for treatment of cancer | STING1, CD47, MYD88 | NPY1R 3534/4885NPY2R 3626/4885NPY4R 3935/4885 |
| US-20220153802-A1 | A STABLE PARENTERAL DOSAGE FORM OF CETRORELIX ACETATE | LPXN, GNRHR, CYP19A1 | NPY1R 65/4885NPY2R 200/4885NPY4R 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.